Novartis sells Elidel for $420 million to Meda
This article was originally published in Scrip
Executive Summary
Novartis is selling manufacturing and marketing rights to the atopic dermatitis treatment Elidel (pimecrolimus 1% cream) to Meda for an up front payment of $420 million.